《新股表現》先聲藥業(02096.HK)暗盤高開5.8%報14.5元 現倒跌14%
根據輝立交易平台顯示,下周二(27日)掛牌的先聲藥業(02096.HK)暗盤高開5.8%報14.5元欠承接,掉頭回落至11元,現造11.74元,較上市價13.7元,低14.3%,成交522萬股。
先聲是內地藥品研發、生產和商業化的公司,目前主要從事仿製藥業務。公司在以下專注戰略性治療領域擁有多元化的產品組合,分別有腫瘤、中樞神經系統及自身免疫疾病。先聲曾於2007年作為當時中國第一家生物和化學製藥公司登陸紐約證券交易所,隨後於2013年將公司私有化。今次來港上市合共發售近2.61億股,並已引入包括Hillhouse Capital、紅土及高新等7名基石投資者,合共認購1.07億股;10%公開發售獲逾588倍超購,已重啟回撥機制佔比增至50%,認購一手中籤率僅5%;股份以招股範圍(12.1-13.7元)上限定價,料集資淨額約33.92億元,主要用於持續研發戰略重點治療領域中選定的在研產品、加強集團銷售和營銷能力、未來幾年投資醫藥或生物技術領域公司及還債等。上市聯席保薦人分別為大摩及中金。(sz/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.